---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039072"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:13:28.978834+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annexon Q2 net loss $35.2M; GA visual function data; GBS enrollment completion in H2 2023

## Summary
- ANX007 (GA) ARCHER Phase 2 data showed dose-dependent preservation of visual function; regulatory engagement planned.
- Phase 3 pivotal trial of ANX005 in GBS enrollment to complete in H2 2023; topline results expected H1 2024.
- Appointed Jamie Dananberg, M.D., as CMO; brings >20 years of drug development experience.
- Cash and equivalents $192.9M as of June 30, providing runway into 2025. Q2 net loss $35.2M ($0.47 per share).
- Upcoming catalysts: ANX1502 Phase 1a data (H2 2023), ANX009 LN Phase 1b data, ALS Phase 2a data.

## SEC filing metadata
- accession: 0000950170-23-039072
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000095017023039072/0000950170-23-039072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000095017023039072/annx-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039072
- JSON: https://secwatch.observer/filing/0000950170-23-039072.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039072.txt

## Key facts
- Earnings Releases
  Annexon, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $35.2 million or $0.47 per share for the quarter ended June 30, 2023, EPS $0.47 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss was $35.2 million or $0.47 per share for the quarter ended June 30, 2023
  - EPS: $0.47 per share
  - Result: reported results
  source text: Annexon, Inc. (the “Company”) announced certain financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528115/000095017023039072/0000950170-23-039072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.